
Regulus Therapeutics Inc. (NASDAQ:RGLS) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
The company plans to initiate phase 1 single-ascending dose (SAD) clinical study in the second quarter, investigating RGLS8429 in healthy volunteers.